Cepheid receives EUA for its SARS-CoV-2 test

Create PDF

March 23, 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for the qualitative detection of SARS-CoV-2. The test is for use on the company’s GeneXpert system, with a detection time of about 45 minutes.